Compare Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 (SLVO) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 vs TG Therapeutics Inc — how do they compare? Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 trades at $65.12, while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: TG Therapeutics Inc is trading nearer its 52-week high, Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 nearer its low. Which is the better fit depends on your goals.
| SLVO | TGTX | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $107.41 | $59.06 |
52-Week Low | $61.81 | $26.39 |
Market Cap | — | $8.26B |
Enterprise Value | — | $8.50B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033
SLVO is an exchange-traded note issued by UBS AG that provides investors with exposure to the performance of a silver-based covered call strategy. The ETN tracks the daily return of the ISE Enhanced 100x Leveraged Silver ETN Index, which combines a long position in silver with a covered call strategy on the silver position. This strategy aims to generate current income from the option premiums, which can provide a buffer during sideways or slightly down markets for silver, but it also caps the potential gains from a significant rise in silver prices. As an ETN, it is subject to the credit risk of the issuer, UBS AG, and has an expiration date of April 21, 2033.
Read more on SLVO →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
